97176 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
HIGHLY GALACTOSYLATED ANTI-TNF-ALPHA ANTIBODIES AND USES THEREOF
#602HIGHLY GALACTOSYLATED ANTI-TNF-ALPHA ANTIBODIES AND USES THEREOF
#603Anti-TMPRSS2 antibodies and antigen-binding fragments
#604USE OF ANTIBODY-COUPLED T CELL RECEPTOR (ACTR) WITH MULTIPLE ANTI-CANCER ANTIBODIES IN CANCER TREATMENT
#605Bispecific antibody and antibody conjugate for tumor therapy and use thereof
#606Compositions and methods for TCR reprogramming using fusion proteins
#607Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
#608Antibodies specific to FCRN
#609IL-15 variants and uses thereof
#610Anti-FcRn antibodies
#611Anti-PD-L1-anti-TIM-3 bispecific antibodies
#612INNATE IMMUNE CELL TRISPECIFIC BINDING PROTEINS AND METHODS OF USE
#613Compositions and methods related to engineered Fc constructs
#614Method for the detection of cells associated with the latent HIV viral reservoir using membrane biomarkers
#615FcγRIIB-specific antibodies and methods of use thereof
#616Immunoglobulin constant region Fc receptor binding agents
#617Triple glucagon/GLP-1/GIP receptor agonist
#618METHOD FOR PRODUCING NK CELL-ENRICHED BLOOD PREPARATION
#619EFFECTOR-DEFICIENT ANTI-CD32A ANTIBODIES
#620SINGLE- AND MULTI-CHAIN CHIMERIC ANTIGEN RECEPTORS
#621Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same
#622Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
#623Chimeric antigen receptors having GITR intracellular domain as co-stimulatory domain
#624RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF
#625HANP-Fc-containing molecular conjugate
#626COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
#627Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
#628METHODS OF PREVENTING OR TREATING SLAMF7 POSITIVE AND SLAMF7 NEGATIVE CANCERS
#629Anti-CTLA-4 antibodies and methods of use thereof
#630ANTIBODY BINDING TO FCRN FOR TREATING AUTOIMMUNE DISEASES
#631Humanized affinity matured anti-FcRn antibodies
#632Multivalent heteromultimer scaffold design and constructs
#633Glucagon/GLP-1 receptor co-agonists
#634Cancer gene therapy targeting CD47
#635Anti-CD3 antibodies and methods of use
#636MODIFIED CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNE THERAPY
#637METHODS AND COMPOSITIONS FOR THE TREATMENT OF INTERVERTEBRAL DISC HERNIATION
#638Anti-metalloprotease antibody for diagnosis and treatment of cancers
#639CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNE THERAPY
#640Heterodimeric proteins and methods for producing and purifying them
#641Antibody polypeptides that antagonize CD40L
#642Covalent diabodies and uses thereof
#643Covalent Diabodies and Uses Thereof
#644CD31 as a molecular target for imaging of inflammation
#645Methods for Suppressing Allergic Reactions
#646Recombinant complement Factor H-immunoglobulin fusion protein with complement regulatory activity, and preparation method therefor and use thereof
#647Fc γ RIII binding fibronectin type III domains, their conjugates and multispecific molecules comprising them
#648IL-2 superagonists in combination with anti-PD-1 antibodies
#649Multispecific NK engager protein
#650Fusion proteins and their related methods
#651Multispecific NK engager protein
#652Engineered antibody Fc variants for enhanced serum half life
#653Composition and method for treating amyotrophic lateral sclerosis
#654IL-15-based fusions to IL-12 and IL-18
#655Interleukin-21 mutein/ anti-PD-1 antibody conjugates
#656Multivalent FV antibodies
#657Monoclonal antibody FnAb8 and application thereof
#658DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT
#659Anti-CD3 antibodies and methods of use
#660ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
#661Modified J-chain
#662Triple glucagon/GLP-1/GIP receptor agonist
#663Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#664Antibodies targeting Fc receptor-like 5 and methods of use
#665Multi-specific binding conjugate, related pharmaceutical compositions and use
#666Anti-HER2 glycoantibodies and uses thereof
#667Means and methods for treating HBV infection and associated conditions
#668IMMUNOMODULATORY PROTEINS
#669Method of culturing NK cells and kits containing medium additions
#670Use of modified Fc fragments in immunotherapy
#671Anti-variant Fc-region antibodies and method of use
#672Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition
#673Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
#674METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASES
#675Fc receptor antibodies and methods of use thereof
#676Monovalent Chimeras
#677Personalized medicine therapeutic MiniCircle
#678Humanized affinity matured anti-FcRn antibodies
#679Anti-PD-L1-anti-TIM-3 bispecific antibodies
#680ANTI-CD3XROB04 BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#681Therapeutic compounds and methods
#682OMALIZUMAB RESISTANT IGE VARIANTS AND THEIR USE IN ANTI-IGE THERAPY
#683Methods and compositions for the detection of Fc receptor binding activity of antibodies
#684Recombinant bacterial host cell for protein expression
#685Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced complement binding
#686Immunity enhancing agent for cancer by Allergin-1 antagonist
#687Coiled-coil connector
#688METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#689METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#690Covalent diabodies and uses thereof
#691Method for the in situ formation of bifunctional immunological complexes
#692Hyaluronic acid-based hydrogels having medical applications
#693Immunoglobulin constant region Fc receptor binding agents
#694Targeted delivery methods and compositions for antihistamines
#695Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
#696Bispecific molecules comprising an HIV-1 envelope targeting arm
#697Anti-transferrin receptor antibodies and methods of use
#698ANTI-FCRN ANTIBODIES
#699Combination of FcgammaRIIB-Specific Antibodies and CD20-Specific Antibodies and Methods of Use Thereof
#700Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy
#701Trispecific binding molecules for treating HBV infection and associated conditions
#702BISPECIFIC ANTIBODY MOLECULE
#703Methods of treating immune diseases by administering antibody polypeptides that specifically bind CD40L
#704Polymeric Fc proteins and methods of screening to alter their functional characteristics
#705Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPα antibody therapy
#706METHOD FOR TREATING A TUMOR WITH BIFUNCTIONAL AGENTS THAT BIND TO TUMOR CARBOHYDRATE ANTIGENS
#707RECEPTOR-TARGETED NANOPARTICLES FOR ENHANCED TRANSCYTOSIS MEDIATED DRUG DELIVERY
#708Domain-exchanged antibody
#709FcRn antibodies and methods of use thereof
#710Methods and means for the production of Ig-like molecules
#711METHOD FOR ENGINEERING IMMUNOGLOBULINS
#712AN IMMUNOTOXIN FOR USE IN THE TREATMENT OF LEISHMANIASIS
#713Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases
#714Glucagon/GLP-1 receptor co-agonists
#715BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES
#716Methods and means for the production of Ig-like molecules
#717Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
#718BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES
#719Human Notch1 decoys
#720FUSION PROTEINS COMPRISING IMMUNOGLOBULIN CONSTANT DOMAIN-DERIVED SCAFFOLDS
#721Modified J-chain
#722Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof
#723Soluble engineered monomeric Fc
#724T-cell redirecting bispecific antibodies for treatment of disease
#725ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
#726Antibodies directed to Fc gamma receptor IIB and Fc epsilon receptor
#727Antibodies With Modified Affinity To FcRn That Promote Antigen Clearance
#728Immunoglobulin constant region Fc receptor binding agents
#729ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION
#730Antibody binding to FcRn for treating autoimmune diseases
#731Antibody binding to FcRn for treating autoimmune diseases
#732Anti-CD3 antibodies and methods of use
#733Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens
#734Multi-chain polypeptide-containing tri-specific binding molecules
#735Modified J-chain
#736ANTIBODY SCAFFOLD FOR HOMOGENOUS CONJUGATION
#737Multivalent heteromultimer scaffold design and constructs
#738CD89 ACTIVATION IN THERAPY
#739USE OF CD-64-BLOCKING AGENTS AS ENHANCER OF AN ANTI-TNF-a ANTIBODY THERAPY
#740COMPOSITIONS AND METHODS FOR PRODUCING GLYCOPROTEINS
#741Antigen binding formats for use in therapeutic treatments or diagnostic assays
#742Method for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
#743Screening of protein candidates
#744Human cytolytic fusion proteins
#745MEDICAMENTS, USES AND METHODS
#746Bispecific antibody fragments for neurological disease proteins and methods of use
#747Immunoconjugates
#748MULTIMERIC FC PROTEINS
#749Compositions and methods related to engineered Fc constructs
#750Heterodimeric proteins and methods for producing and purifying them
#751COMPOSITIONS AND METHODS FOR SIMULTANEOUS BIVALENT AND MONOVALENT CO-ENGAGEMENT OF ANTIGENS
#752METHODS, COMPOSITIONS AND KITS FOR CELL SPECIFIC MODULATION OF TARGET ANTIGENS
#753Engineered antibody FC variants
#754METHODS TO MANIPULATE ALPHA-FETOPROTEIN (AFP)
#755Recombinant IgG4 monovalent antibodies
#756Multi-functional mucosal vaccine platform
#757MULTIMERIC FC PROTEINS
#758T-cell redirecting bispecific antibodies for treatment of disease
#759Compositions and methods for modulating an immune response
#760RECEPTOR-TARGETED NANOPARTICLES FOR ENHANCED TRANSCYTOSIS MEDIATED DRUG DELIVERY
#761Hybrid constant regions
#762Multispecific NK engager proteins
#763Anti-CTLA-4 antibodies and methods of use thereof
#764Humanized and affinity matured antibodies to FcRH5 and methods of use
#765BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES
#766Covalent diabodies and uses thereof
#767Immunoglobulin constant region Fc receptor binding agents
#768Effector-deficient anti-CD32a antibodies
#769OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
#770METHOD OF INHIBITING METASTASIS OF CANCER CELLS AND MODULATING AUTOIMMUNE DISEASES USING GAL-3BP-Fc FUSION PROTEIN
#771Optimized Fc variants and methods for their generation
#772Molecular constructs for treating central nervous system diseases
#773Molecular constructs for treating infectious diseases
#774Molecular constructs with targeting and effector moieties for treating infectious diseases
#775Molecular constructs with targeting and effector moieties comprising an SCFV specific for ectodomain of transferrin-1 receptor and fingolimod
#776Peptide core-based multi-arm linkers for treating infectious diseases
#777Peptide core-based multi-arm linkers for treating central nervous system diseases
#778Peptide core-based multi-arm linkers and their applications
#779Anti-CD19 antibodies
#780Optimized Fc variants and methods for their generation
#781Methods of producing antibodies to neonatal Fc receptor (FcRn)
#782BISPECIFIC ANTIBODY WITH TWO SINGLE-DOMAIN ANTIGEN-BINDING FRAGMENTS
#783IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
#784METHODS OF REDUCING SERUM LEVELS OF FC-CONTAINING AGENTS USING FCRN ANTAGONISTS
#785Antibodies specific to FcRn
#786Immunoconjugates
#787HETEROMULTIMER CONSTRUCTS OF IMMUNOGLOBULIN HEAVY CHAINS WITH MUTATIONS IN THE FC DOMAIN
#788COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
#789STABLE SOLID UNITS AND METHODS OF MAKING THE SAME
#790MONOVALENT ANTIBODY FRAGMENTS USEFUL AS THERAPEUTICS
#791FC RECEPTOR BINDING PROTEINS
#792FC RECEPTOR BINDING PROTEINS
#793FC RECEPTOR BINDING PROTEINS
#794FC RECEPTOR BINDING PROTEINS
#795FC RECEPTOR BINDING PROTEINS
#796Non-human mammals for the production of chimeric antibodies
#797Non-human mammals for the production of chimeric antibodies
#798Fc-binding protein, method for producing said protein, and antibody adsorbent using said protein, and methods for purifying and identifying antibody using said adsorbent
#799Non-human mammals for the production of chimeric antibodies
#800Non-human mammals for the production of chimeric antibodies
#801Non-human mammals for the production of chimeric antibodies
#802Multivalent heteromultimer scaffold design and constructs
#803Means and methods for treating HBV infection and associated conditions
#804FC RECEPTOR BINDING PROTEINS
#805Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
#806Fusion proteins and their related methods
#807Anti-Fc-gamma receptor IIB antibodies and uses thereof
#808Methods and means for the production of Ig-like molecules
#809T-cell redirecting bispecific antibodies for treatment of disease
#810Covalent diabodies and uses thereof
#811Effector-deficient anti-CD32A antibodies
#812Fc variants with improved complement activation
#813FcRn-specific human antibody and composition for treatment of autoimmune diseases
#814Gastrin peptide immunogenic composition
#815Interferon lambda-antibody complexes
#816METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#817Anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
#818Production of antibody formats and immunological applications of said formats
#819Antibody polypeptides that antagonize CD40L
#820Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
#821METHODS AND THERAPEUTICS COMPRISING LIGAND-TARGETED ELPs
#822TETRAVALENT BISPECIFIC ANTIBODIES
#823Coiled coil and/or tether containing protein complexes and uses thereof
#824METHOD FOR ENGINEERING IMMUNOGLOBULINS
#825Glucagon/GLP-1 receptor co-agonists
#826Highly galactosylated anti-TNF-α antibodies and uses thereof
#827Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
#828HUMAN IGG1 FC REGION VARIANTS AND USES THEREOF
#829Anti-HER2 glycoantibodies and uses thereof
#830ANTI-CD20 GLYCOANTIBODIES AND USES THEREOF
#831FcGammaRIIB Specific Antibodies and Methods of Use Thereof
#832FcGammaRIIB Specific Antibodies and Methods of Use Thereof
#833Heterodimerized polypeptide
#834USE OF ANTI-FCYRI AND/OR ANTI-FCYRIIA ANTIBODIES FOR TREATING ARTHRITIS, INFLAMMATION, THROMBOCYTOPENIA AND ALLERGIC SHOCK
#835Immunoproteases
#836Glyco-engineered antibodies
#837Microtubule-modifying compound
#838Anti-CD19 Antibodies
#839GLYCOPROTEIN PREPARATIONS
#840Depletion of cancer stem cells
#841Anti-CD16 binding molecules
#842Mouse FcγammaRII-specific Fc antibody
#843Engineered immunoglobulin FC polypeptides
#844Deimmunized serum-binding domains and their use in extending serum half-life
#845Anti-CD3 antibodies and methods of use
#846METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES
#847Bispecific antibody molecule
#848Anti-FcRn antibodies
#849Recombinant bacterial host cell for protein expression
#850Anti-FcRH5 antibodies
#851HYBRID CONSTANT REGIONS
#852Stably tethered structures of defined compositions with multiple functions or binding specificities
#853Soluble engineered monomeric Fc
#854Methods and compositions for inhibiting CD32B expressing cells
#855Methods and compositions for inhibiting CD32b expressing cells
#856Antibody polypeptides that antagonize CD40L
#857FcγRIIB-specific antibodies and methods of use thereof
#858OPTIMIZED Fc VARIANTS
#859Monoclonal antibodies against CD32b
#860Method for diagnosing breast cancer by detection of polymeric immunoglobulin receptor in vesicles isolated from patients
#861Molecules with extended half-lives, compositions and uses thereof
#862IMMUNOGLOBULIN FC VARIANTS
#863Bispecific antibody fragments for neurological disease proteins and methods of use
#864ANTIGEN-BINDING MOLECULE FOR PROMOTING ELIMINATION OF ANTIGENS
#865Combination of FcγRIIB-specific antibodies and CD20-specific antibodies and methods of use thereof
#866Methods for suppressing allergic reactions
#867Human neonatal Fc receptor antibodies and methods of use thereof
#868FC VARIANTS THAT IMPROVE FCRN BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
#869Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
#870Human Notch1 decoys
#871Antibodies to FeRn and uses thereof
#872Tetrameric cytokines with improved biological activity
#873Methods and means for the production of IG-like molecules
#874Fc VARIANTS
#875Anti-FcRH5 antibodies and immunoconjugates and methods of use
#876Nucleic acids encoding antibody polypeptides that antagonize CD40L
#877Methods and means for the production of Ig-like molecules
#878T-cell redirecting bispecific antibodies for treatment of disease
#879ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE
#880Antigen binding formats for use in therapeutic treatments or diagnostic assays
#881SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS
#882PEANUT ALLERGY TREATMENT
#883Methods and means for the production of Ig-like molecules
#884Antibody Scaffold For Homogenous Conjugation
#885Methods and compositions for inhibiting CD32B expressing cells
#886CD89 activation in therapy
#887Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
#888Molecules with extended half-lives, compositions and uses thereof
#889Combined use of Fc gamma RIIb (CD32B) and CD20-specific antibodies
#890Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
#891Optimized Fc variants
#892Methods of treating autoimmune diseases with anti-FcεRI antibodies
#893Heterodimeric human IgG1 polypeptides with isoelectric point modifications
#894Interferon lambada-antibody complexes
#895Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock
#896Antibodies with Enhanced or Suppressed Effector Function
#897Antibody polypeptides that antagonize CD40L
#898Antibodies with enhanced or suppressed effector function
#899Anti-FcRH5 antibodies and immunoconjugates and methods of use
#900Fc receptor binding proteins